Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Alfa-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00132106
Recruitment Status : Unknown
Verified August 2007 by Radboud University.
Recruitment status was:  Recruiting
First Posted : August 19, 2005
Last Update Posted : August 31, 2007
Sponsor:
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Radboud University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The activity of the sympathetic nervous system seems to influence the uptake (and handling) of glucose by the skeletal muscle of the forearm. Conditions in which sympathetic activity is increased seem to inhibit/reduce forearm glucose uptake. Inversely a decrease in sympathetic activity seems to increase glucose uptake. This study analyzes the effect of alfa-adrenergic receptor blockade (counteracting sympathetic influence) on insulin-stimulated forearm glucose uptake in patients with increased sympathetic activity (patients with chronic heart failure).

Condition or disease Intervention/treatment Phase
Heart Failure, Congestive Drug: phentolamine Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: The Effect of a-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure
Study Start Date : August 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. change in glucose uptake

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Heart failure of at least New York Heart Association (NYHA) class II
  • Left ventricular ejection fraction (LVEF) <= 40%
  • Age 18-75 years

Exclusion Criteria:

  • Alfa-blockers, or beta-blockers with alfa-blocking activity (carvedilol)
  • Tricyclic antidepressants
  • Warfarin derivatives (acetylic salicylic acid and clopidogrel are allowed)
  • Hospitalisation in 6 weeks prior to the study
  • Any change in medication in 6 weeks prior to the study
  • Unstable angina
  • Orthopnoea
  • Known chronic disease of the autonomic nervous system
  • Diabetes mellitus
  • Oedema of the lower extremities, complicating the insertion of a venous catheter in a vein on the foot
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00132106


Contacts
Layout table for location contacts
Contact: Marc E.R. Gomes, MD +31-24-3614533/3616550 m.gomes@cardio.umcn.nl

Locations
Layout table for location information
Netherlands
Radboud University Nijmegen Medical Centre Recruiting
Nijmegen, Netherlands, 6500 HB
Contact: Marc ER Gomes, MD    31-24-3614533/3616550    m.gomes@cardio.umcn.nl   
Sub-Investigator: Marc ER Gomes, MD         
Sub-Investigator: Alexandra H Mulder, MD         
Sub-Investigator: Freek WA Verheugt, MD, PhD         
Sub-Investigator: Paul Smits, MD, PhD         
Principal Investigator: Cees J Tack, MD, PhD         
Sub-Investigator: Louise Bellersen, MD         
Sponsors and Collaborators
Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
Layout table for investigator information
Principal Investigator: Cees J Tack, MD, PhD Radboud University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00132106    
Other Study ID Numbers: CHFALFA
First Posted: August 19, 2005    Key Record Dates
Last Update Posted: August 31, 2007
Last Verified: August 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Phentolamine
Adrenergic alpha-Antagonists
Adrenergic Antagonists
 Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antihypertensive Agents